The binding of [3H]AF-DX 384 is reduced in the caudate-putamen of subjects with schizophrenia.
Clinical studies of cholinergic pharmacotherapy, together with the putative role of the muscarinic receptor system in the neurophysiology of human behavior, support a possible muscarinic cholinergic involvement in schizophrenia. The present study has measured the density of [3H]AF-DX 384 labelled receptors (muscarinic M2 and M4) in the caudate-putamen, obtained at autopsy, from 19 subjects who had schizophrenia, and 20 subjects who did not have schizophrenia. [3H]AF-DX 384 binding was reduced in caudate-putamen from schizophrenic subjects (104 +/- 10.3 vs 145 +/- 901 fmol mg(-1) TE; mean +/- s.e.; p = 0.007). Preliminary analysis of patient drug data as well as rat studies suggest that the reduced [3H]AF-DX 384 binding in caudate-putamen of schizophrenic subjects is not wholly due to antipsychotic drug treatment, or anticholinergic medication for the treatment of extrapyramidal effects. These data suggest that the muscarinic cholinergic system may be involved in the pathology of schizophrenia.
Crook
J M
JM
The Rebecca L. Cooper Research Laboratories, The Mental Health Research Institute of Victoria, Parkville, Australia. jcrook@cooper.mhri.edu.au
Dean
B
B
Pavey
G
G
Copolov
D
D
D000328:Adult; D000368:Aged; D000818:Animals; D014150:Antipsychotic Agents / Q000494:pharmacology; D002421:Caudate Nucleus / Q000378:metabolism*; D005260:Female; D006801:Humans; D008297:Male; D008875:Middle Aged; D018727:Muscarinic Antagonists / Q000378:metabolism*; D010890:Pirenzepine / Q000031:analogs & derivatives* / Q000378:metabolism; D011699:Putamen / Q000378:metabolism*; D051381:Rats; D017207:Rats, Sprague-Dawley; D012559:Schizophrenia / Q000378:metabolism*
D014150:Antipsychotic Agents; D018727:Muscarinic Antagonists; C065959:AFDX 384; D010890:Pirenzepine